

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




FIG. 1A




FIG. 1B




FIG. 1C

5/7/95




FIG-2A




FIG-2B




FIG-3




FIG-4A




FIG-4B






FIG-4C

CD8 + T cells are the effector cells



E:T

Fig. 5



Effector to target ratio

Fig. 6






FIG. 7


EFFECT OF PLURONIC/TWEEN ON CTL PRIMING



EFFECT OF SQUALANE/TWEEN ON CTL PRIMING



EFFECT OF SQUALANE /PL URONIC ON CTL PRIMING



COMPARISON OF 30 ug OVA IN CUSTOM
3 OR 2 COMPONENT ADJUVANTS




Fig. 11

Induction of anti-gp120IIb antibodies in monkeys




Fig. 12

**Antitumor activity of HOPE2 Cells after a Single Immunization
(Day 10) of Soluble E7 Protein in Adjuvant**




Fig. 13

**Antitumor Activity of HOPE2 Cells after a Two Immunizations
(Day 10, 19) of Soluble E7 Protein in Adjuvant**




Figure 14